相关实验视频

Updated: Jan 16, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

676

第一线[Lu]Lu-PSMA-617治疗没有ADT,化疗或局部治疗的转移性激素敏感前列腺癌.

Vinay K Giri1,2, Gerald M Kolodny1,3, Marc B Garnick4,2

  • 1Harvard Medical School, Boston, Massachusetts.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
|September 25, 2025
PubMed
概括

一名患有转移性前列腺癌的患者在接受 lutetium-177 vipivotide tetraxetan ([177Lu]Lu-PSMA-617) 的一线治疗后显著改善. 这种向治疗在原发性瘤和转移性病变中都表现出有效性,为传统治疗提供了潜在的替代方案.

关键词:
第一个行[177Lu]Lu-PSMA-61717转移性转移性 转移性前列腺癌是前列腺癌.放射性药物 放射性药物 放射性药物

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K